La vendita allo scoperto per REX American Resources dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di REX American Resources. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

REX American Resources (NYSE:REX) Azioni, Report sulle vendite allo scoperto

REX American Resources

REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.

REX American Resources Corp

REX INTL HOLDINGS LTD ORD by Rex International Holdings Ltd

Rex International Holding Ltd

RIDEON EXPRESS HLDGS by Rideon Express Holdings

RIDE ON EXPRESS Holdings Co Ltd

Rexford Industrial Realty, Inc. Common Stock

Rexford Industrial Realty Inc

Rexford Industrial Realty, Inc. 5.875% Series B Cumulative Redeemable Preferred Stock

Rexford Industrial Realty, Inc. 5.625% Series C Cumulative Redeemable Preferred Stock, par value $0.01 per share

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $60 price target.

News

Price Target

Reiteration

Analyst Ratings

Truist Securities Reiterates Buy on REX American Resources, Maintains $60 Price Target

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.54 by 29.63 percent. This is a 34.62 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $148.16 million which beat the analyst consensus estimate of $146.00 million by 1.48 percent. This is a 30.11 percent decrease over sales of $211.98 million the same period last year.

Earnings

Earnings Beats

REX American Resources Q2 2024 GAAP EPS $0.70 Beats $0.54 Estimate, Sales $148.16M Beat $146.00M Estimate

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $65 to $60.

Truist Securities Maintains Buy on REX American Resources, Lowers Price Target to $60

Ratings for REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for REX American Resources, presenting an average target of $64.5, a high estimate of $70.00, and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 2.79% increase from the previous average price target of $62.75.
<img src="https://www.benzinga.com/files/images/story/2024/1718647280_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive REX American Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to REX American Resources. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of REX American Resources compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for REX American Resources's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of REX American Resources's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/REX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on REX American Resources analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind REX American Resources</h2>
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
<h3>REX American Resources's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining REX American Resources's financials over 3 months reveals challenges. As of 30 April, 2024, the company experienced a decline of approximately -24.2% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: REX American Resources's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): REX American Resources's ROE excels beyond industry benchmarks, reaching 1.96%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): REX American Resources's ROA excels beyond industry benchmarks, reaching 1.53%. This signifies efficient management of assets and strong financial health.
Debt Management: REX American Resources's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For REX American Resources

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $65 price target.

Truist Securities Maintains Buy on REX American Resources, Maintains $65 Price Target

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $70 to $65.

Truist Securities Reiterates Buy on REX American Resources, Lowers Price Target to $65

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.40 by 45 percent. This is a 93.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $165.28 million by 2.45 percent. This is a 24.20 percent decrease over sales of $212.71 million the same period last year.

Earnings Misses

REX American Resources Q1 EPS $0.58 Beats $0.40 Estimate, Sales $161.23M Miss $165.28M Estimate

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and raises the price target from $58 to $70.

Truist Securities Reiterates Buy on REX American Resources, Raises Price Target to $70

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $58 price target.

Truist Securities Maintains Buy on REX American Resources, Maintains $58 Price Target

Shares of Kodiak Sciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kod#NASDAQ">KOD</a>) fell sharply during Thursday&rsquo;s session after the company reported a wider-than-expected fourth-quarter loss.
Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xlo#NASDAQ">XLO</a>) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) shares climbed 80% to $1.5395. Biodexa&#39;s MTX110 showed promise in extending life expectancy against aggressive brain cancers.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) gained 55% to $0.9239.</li>
<li>Binah Capital Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcg#NASDAQ">BCG</a>) gained 48% to $14.05 after dipping more than 20% on Wednesday.</li>
<li>Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.</li>
<li>Allego N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allg#NASDAQ">ALLG</a>) rose 32.8% to $1.7650.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 26% to $22.15.</li>
<li>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) gained 23.2% to $54.15 following upbeat earnings.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) gained 22.8% to $4.6050.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) gained 22.7% to $2.00.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) gained 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) rose 16.8% to $2.2802.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) rose 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 15.5% to $14.52 after jumping over 100% on Wednesday.</li>
<li>Sutro Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stro#NASDAQ">STRO</a>) surged 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares rose 14.1% to $0.1021. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) gained 12.7% to $1.0250.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) climbed 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health&#39;s Diagnostics Business.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) climbed 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 10.4% to $24.37.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) rose 7.1% to $1.1786. Ginkgo Bioworks announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) gained 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primech Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmec#NASDAQ">PMEC</a>) shares fell 46.7% to $2.07 after the company issued financial updates and corporate highlights for the six months ended Sept. 30, 2023.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) fell 28.1% to $0.0427. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.</li>
<li>Data Storage Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtst#NASDAQ">DTST</a>) dipped 24% to $5.81 following fourth-quarter results.</li>
<li>urban-gro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ugro#NASDAQ">UGRO</a>) declined 22.9% to $1.3992 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) fell 22% to $0.1493. Presto Automation recently entered securities purchase agreements relating to the issuance and sale of 4.8 million shares</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnxp#NASDAQ">TNXP</a>) dipped 19.6% to $0.2629. Tonix Pharmaceuticals announced pricing of $4.4 million registered direct offering.</li>
<li>MillerKnoll, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlkn#NASDAQ">MLKN</a>) shares fell 17.2% to $25.28 as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.</li>
<li>Sezzle Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sezl#NASDAQ">SEZL</a>) fell 16.6% to $77.13.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) fell 16.3% to $0.2616. NuCana announced a plan to implement 1-for-25 ADS ratio change.</li>
<li>SOBR Safe, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sobr#NASDAQ">SOBR</a>) fell 13.7% to $0.4460 after gaining 12% on Wednesday.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 13% to $12.97.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) fell 12.5% to $ 0.1151 as the company posted fourth-quarter results and announced stock split of 1-for-16.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) declined 10.9% to $1,710.01.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) fell 10.3% to $1.56 after gaining over 22% on Wednesday.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) fell 10.2% to $0.0678 after dipping 20% on Wednesday.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 10.2% to $0.70.</li>
<li>Reddit, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) fell 9.4% to $52.32.</li>
<li>Braze, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brze#NASDAQ">BRZE</a>) dipped 9.3% to $45.90 after the company issued soft EPS guidance for FY25.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares dropped 6.2% to $27.09 after the company reported fourth-quarter results. The company also said it identified four material weaknesses amid its internal control over financial reporting.</li>
<li>GCT Semiconductor Holding Inc, (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) fell 5.1% to $41.77 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>Carnival Corporation &amp; plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) fell 4% to $16.52. Carnival posted a narrower-than-expected loss for its first quarter on Wednesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39; </a>

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABTS

AKAN

ALLG

AVTX

BDRX

BRZE

CERO

CZOO

DTST

DXYZ

GCTS

GMDA

HKIT

Kintara Therapeutics, Inc. - Common Stock

KTRA

MARA

MLKN

MRNO

MSTR

MTTR

MVLA

NCNA

NKLA

NTRB

OTRK

PMEC

PRST

RDDT

SEZL

SMMT

SOBR

STRO

TNXP

UGRO

XXII

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding <a href="https://www.benzinga.com/topic/interest-rates">interest rate reductions</a>.
On Wednesday, Fed Governor Christopher J. Waller spoke in opposition to an early interest rate cut, citing the still uncertain inflation path, and noted that his stance is shared by a robust share <a href="https://www.benzinga.com/economics/macro-economic-events/24/03/37983526/feds-waller-sends-shiver-down-investors-spines-there-is-no-rush-to-cut-interest-r">of the Fed board</a>.
Thursday saw an upward revision to the fourth-quarter U.S. gross domestic product, with the economy expanding by 3.4% on an annualized basis, exceeding <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/03/37981569/us-economic-growth-upwardly-revised-to-3-4-in-q4-jobless-claims-slow-thursdays-economi">the previously estimated 3.2%.</a>
Traders marginally scaled back their bets on a June rate cut scenario, now placing the likelihood at 64%, down from 70% on Wednesday, according to the CME Group&#8217;s FedWatch tool.
While the S&amp;P 500 and the Dow remained unchanged for the day, the Nasdaq 100 eased by 0.2%, influenced by reduced rate cut expectations and increasing commodity prices that weighed on tech companies.
Gold surged to $2,225 per ounce intraday during midday trading in New York, reaching new all-time highs. WTI light crude prices climbed by 1.2% to $82.50 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rebounded beyond $70,700, displaying remarkable resilience despite the pause in risk appetite toward stocks.
As we approach the final trading day of March, U.S. major averages are poised to conclude their fifth consecutive month of gains. Interestingly, this month has seen small caps, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), outperform large-cap indices.
<h3 class="wp-block-heading">Thursday&#8217;s Performance On Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
<td>MTD %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,127.97</td>
<td>0.6%</td>
<td>3.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,255.38</td>
<td>0.0%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,790.12</td>
<td>0.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,261.57</td>
<td>-0.2%</td>
<td>1.2%</td>
</tr>
</tbody>
</table>
</figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was flat at $523.34, the&nbsp;SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was unchanged at $397.73 and the tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.2% to $444.33, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Sector-wise, the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.9%, while the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) was the laggard, down 0.2%.
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
<ul>
<li>Gold mining stocks rallied Thursday as the precious metal updated record highs. Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) was up 2.8%, Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) 2.2% and Agnico Eagle Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) 2.7%. </li>
<li>Nikola Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NYSE">NKLA</a>) surged by over 11%, fueled by rumors of a short squeeze circulating within the Reddit community.</li>
<li>The Estée Lauder Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) rose more than 6% after the company announced a deal with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to distribute the Clinique brand through the retail giant&#8217;s platform.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose over 17% after reporting better-than-expected results last quarter. </li>
<li>Other companies reacting to earnings were Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), up 2.5%, MSC Industrial Direct Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSN#NYSE">MSN</a>) down 2%, REX American Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>), up 30% and Perspective Therapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), down 1%. </li>
<li>Companies set to report after the close are Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), Oxford Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) and Immunome Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>). </li>
</ul>
Read now:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37973448/more-than-a-third-of-gen-z-millennials-lean-on-family-support-for-home-purchases-ma"> More Than A Third Of Gen Z, Millennials Lean On Family Support For Home Purchases: &#8216;Many Get Help From Mom And Dad,&#8217; Reveals Redfin</a>
Photo via Shutterstock.

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

ETFs

$BTC

AMZN

CATX

SPDR Dow Jones Industrial Average ETF Trust

GOLD

IMNM

SMTC

XLRE

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?

WIIM

REX American Resources shares are trading higher after the company reported better-than-expected Q4 GAAP EPS results.

U.S. stocks were slightly higher, with the S&amp;P 500 gaining around 0.1% on Thursday.
Shares of REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) rose sharply during Thursday&rsquo;s session following <a href="https://www.benzinga.com/quote/REX/earnings">upbeat quarterly earnings.</a>
REX American Resources posted quarterly GAAP earnings of $1.16 per share, versus market estimates of 68 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
REX American Resources shares jumped 23.2% to $54.15 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares gained 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) surged 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) gained 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.</li>
<li>Sutro Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stro#NASDAQ">STRO</a>) climbed 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) rose 12.7% to $1.0250.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) rose 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health&#39;s Diagnostics Business.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) climbed 10.4% to $24.37.</li>
<li>Guardant Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gh#NASDAQ">GH</a>) gained 8.4% to $19.48.</li>
<li>Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) surged 8% to $3.1850.</li>
<li>Arhaus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arhs#NASDAQ">ARHS</a>) gained 7.7% to $15.94.</li>
<li>Riot Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) rose 6.8% to $13.07.</li>
<li>BRP Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dooo#NASDAQ">DOOO</a>) gained 6.4% to $67.74 after the company reported fourth-quarter results.</li>
<li>Encompass Health Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ehc#NYSE">EHC</a>) gained 5.8% to $82.06. Barclays analyst Andrew Mok maintained Encompass Health with an Overweight and raised the price target from $95 to $101.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) rose 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.</li>
<li>Exact Sciences Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>) gained 4.7% to $70.01.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37984469/bitcoin-trades-above-70-000-following-gdp-jobless-claims-data-gatetoken-emerges-as-top-gai"> Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer</a>

ARHS

DOOO

EXAS

OPEN

RIOT

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $0.68 by 70.59 percent. This is a 146.81 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $187.61 million which missed the analyst consensus estimate of $190.26 million by 1.39 percent. This is a 6.27 percent decrease over sales of $200.17 million the same period last year.

CORRECTION: REX American Resources Q4 GAAP EPS $1.16 Beats $0.68 Estimate, Sales $187.61M Miss $190.26M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DRIO

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

ZVRA

Earnings Scheduled For March 28, 2024

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that REX American Resources will report an earnings per share (EPS) of $0.68. 
REX American Resources bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.81, which was followed by a 3.79% drop in the share price the next day.
Here's a look at REX American Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.68</td>
<td>0.66</td>
<td>0.08</td>
<td>0.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.49</td>
<td>0.52</td>
<td>0.30</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711555260_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of REX American Resources were trading at $43.8 as of March 26. Over the last 52-week period, shares are up 54.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/REX/earnings">To track all earnings releases for REX American Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REX American Resources's Earnings Outlook

As of Dec. 1, 2023, four stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>)</h3>
<ul>
<li>On Nov. 30, REX American Resources reported better-than-expected third-quarter financial results. REX American Resources&rsquo; Chief Executive Officer, Zafar Rizvi, commented, &quot;Our fiscal third quarter results mark the best quarterly net income and earnings per share results in our 39 year history as a public company and highlights the strength of our ethanol operations.&quot; The company&rsquo;s stock jumped around 33% over the past five days and has a <a href="https://www.benzinga.com/quote/REX">52-week high of $51.19 </a>.</li>
<li>RSI Value: 85.13</li>
<li>REX Price Action: Shares of REX American Resources jumped 32.9% to close at $49.02 on Thursday.</li>
</ul>
<h3>Phillips 66 (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/psx#NYSE">PSX</a>)</h3>
<ul>
<li>Phillips 66 confirmed ongoing discussions with Elliot Investment Management. Elliot disclosed a $1 billion stake in the company and planned to seek board seats. The company&rsquo;s stock gained around 9% over the past five days and <a href="https://www.benzinga.com/quote/PSX"> has a 52-week high </a> of $129.75.</li>
<li>RSI Value: 75.71</li>
<li>PSX Price Action: Shares of Phillips 66 gained 5.5% to close at $128.89 on Thursday.</li>
</ul>
<h3>New Fortress Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nfe#NASDAQ">NFE</a>)</h3>
<ul>
<li>On Nov. 8, New Fortress Energy reported better-than-expected third-quarter revenue results and reaffirmed FY23 and FY24 adjusted EBITDA guidance. &quot;Our transition to core infrastructure has begun as nearly 100% of third quarter earnings came from contracted downstream assets. We have visibility into downstream earnings growth given the recent commencement of operations at our second power plant in Puerto Rico combined with the start-up of our first FLNG unit and Brazilian terminal and power plant. With lower capital expenditures and an estimated $1 billion in non-core asset sales, we are in an incredible position to deleverage and focus on high return organic growth opportunities,&quot; said Wes Edens, NFE president and chief executive officer. The company&rsquo;s stock jumped around 26% over the prior month and has a <a href="https://www.benzinga.com/quote/NFE"> 52-week high </a> of $52.13.</li>
<li>RSI Value: 71.56</li>
<li>NFE Price Action: Shares of New Fortress Energy gained 2.7% to close at $38.48 on Thursday.</li>
</ul>
<h3>Cheniere Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lng#NYSE">LNG</a>)</h3>
<ul>
<li>On Nov. 2, Chenire Energy posted better-than-expected quarterly sales. &quot;The third quarter was marked by key milestones achieved across the Cheniere platform, highlighted by the production of our 3,000th LNG cargo since start-up in 2016. Cheniere achieved that production milestone faster than any other LNG operator in history, which is further evidence of our dedication to operational excellence,&quot; said Jack Fusco, Cheniere&rsquo;s President and Chief Executive Officer. The company&rsquo;s stock gained around 8% over the past month and has a 52-week high is $183.24.</li>
<li>RSI Value: 70.95</li>
<li>LNG Price Action: Shares of Cheniere Energy rose 1% to close at $182.15 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/11/36016689/how-to-make-500-a-month-with-pfizer-stock"> How To Make $500 A Month With Pfizer Stock </a>

Short Ideas

Pre-Market Outlook

Top 4 Energy Stocks That May Implode This Quarter

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday.
The Dow traded up 0.88% to 35,742.35 while the NASDAQ fell 0.79% to 14,145.17. The S&amp;P 500 also fell, dropping, 0.15% to 4,543.88.
Check This Out: <a href="https://www.benzinga.com/news/23/11/36020064/salesforce-to-rally-over-30-here-are-10-top-analyst-forecasts-for-thursday"> Salesforce To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Thursday</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares rose by 0.8% on Thursday.
In trading on Thursday, communication services shares fell by 1.7%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbrl#NASDAQ">CBRL</a>) fell around 6% on Thursday after the company released results for its first quarter.
The company reported quarterly revenues of $823.8 million, down 1.9% Y/Y, missing the consensus of $826.21 million. Adjusted EPS of $0.51, a 48% decrease from $0.99 a year ago, missing the consensus of $0.75.
Cracker Barrel expects FY24 revenue of $3.4 billion to $3.5 billion, versus the consensus of $3.5 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 244% to $1.43 after the company announced it received FDA IND clearance for the Phase 2 clinical trial of dusquetide in the treatment of aphthous ulcers of Beh&ccedil;et&#39;s disease.
Shares of REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) got a boost, shooting 35% to $49.84 after the company reported better-than-expected third-quarter financial results.
ImmunoGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imgn#NASDAQ">IMGN</a>) shares were also up, gaining 82% to $29.30 after AbbVie announced it will acquire the company in a transaction valued at $31.26 per share in cash.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Lizhi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lizi#NASDAQ">LIZI</a>) shares dropped 26% to $2.8115 following third-quarter results.
Shares of POET Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poet#NASDAQ">POET</a>) were down 23% to $0.8602 after the company reported pricing of $1.4 million underwritten public offering of common shares and warrants.
Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) was down, falling 14% to $32.67 after the company reported worse-than-expected third-quarter revenue results and issued FY24 revenue guidance below estimates.
Also Check This Out:<a href="https://www.benzinga.com/news/earnings/23/11/36016689/how-to-make-500-a-month-with-pfizer-stock"> How To Make $500 A Month With Pfizer Stock</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.7% to $76.53 while gold traded down 0.5% at $ 2,057.70.
Silver traded up 0.7% to $25.615 on Thursday while copper rose 0.7% to $3.8515.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 gained 0.55%, London&rsquo;s FTSE 100 rose 0.41% while Spain&rsquo;s IBEX 35 Index fell 0.04% The German DAX rose 0.30% French CAC 40 rose 0.59%, while Italy&rsquo;s FTSE MIB Index rose 0.16%.
The eurozone unemployment rate came in unchanged at 6.5% in October, while inflation rate fell to 2.4% year-over-year in November, recording its lowest level since July 2021.
The annual inflation rate in Italy slowed to 0.8% in November from 1.7% in the prior month. Spain posted a current account surplus of EUR 3,455 million in September versus a year-ago surplus of EUR 451 million. German jobless rate increased to 5.9% in November from 5.8% in October. The French economy shrank 0.1% on quarter in the third quarter, while consumer price inflation fell to 3.4% year-over-year in November.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Thursday, with Japan&rsquo;s Nikkei 225 gaining 0.50%, Hong Kong&rsquo;s Hang Seng Index rising 0.29% and China&rsquo;s Shanghai Composite Index gaining 0.26%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, climbed 0.13%.
Indian fiscal deficit rose to INR 8.04 trillion in April-October from INR 7.58 trillion in the year-ago period. Retail sales in Hong Kong climbed 2.7% year-over-year in October versus a revised 10.0% surge in the prior month.
Retail sales in Japan increased 4.2% year-over-year in October. Japanese housing starts fell by 6.3% year-over-year in October, while consumer confidence index rose to 36.1 in November from 35.7. The NBS Composite PMI Output Index for China fell to 50.4 in November from 50.7 in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
Personal spending in the U.S. increased by 0.2% from a month ago in October compared to a 0.7% rise in September.
Personal income rose 0.2% month-over-month in October.
U.S. initial jobless claims increased by 7,000 to 218,000 in the week ending Nov. 25, versus the revised reading of 211,000 in the prior week, and compared to market estimates of 220,000.
The personal consumption expenditure price index in the U.S. came in flat month-over-month in October following a 0.4% increase in September. Annual core PCE inflation eased to 3.5% from 3.7%.
The Chicago PMI rose to 55.8 in November from 44 a month ago.
Pending home sales in the U.S. fell 1.5% month-over-month in October.
U.S. natural-gas supplies climbed 10 billion cubic feet last week, the EIA said.
Now Read This: <a href="https://www.benzinga.com/news/23/11/36021262/top-4-defensive-stocks-that-you-may-want-to-dump-in-november"> Top 4 Defensive Stocks That You May Want To Dump In November</a>

Eurozone

Global

CBRL

IMGN

LIZI

POET

PSTG

SNGX

Nasdaq Falls Over 100 Points; Cracker Barrel Shares Slide After Q1 Results

Shares of Titan Machinery Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/titn#NASDAQ">TITN</a>) moved lower during Thursday&rsquo;s trading following weak quarterly results.
Titan Machinery posted quarterly earnings of $1.32 per share, missing market estimates of $1.53 per share. The company&rsquo;s quarterly sales came in at $694.12 million versus estimates of $727.20 million.
Titan Machinery shares declined 8.1% to $23.41 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Minim Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares jumped 700% to $7.36 after gaining over 13% on Wednesday.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) gained 174% to $2.47.</li>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) surged 116% to $0.90 after the company announced it received FDA IND clearance for the Phase 2 clinical trial of dusquetide in the treatment of aphthous ulcers of Beh&ccedil;et&#39;s disease.</li>
<li>ImmunoGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imgn#NASDAQ">IMGN</a>) shares jumped 80% to $28.89 after AbbVie announced it will acquire the company in a transaction valued at $31.26 per share in cash.</li>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) gained 46% to $2.2221.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares climbed 45% to $5.00.</li>
<li>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) gained 30.7% to $48.22 following strong third-quarter results.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) rose 24.2% to $5.03 after surging 22% on Wednesday. Clearmind Medicine recently announced results from its weight loss and metabolic disorder program.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) gained 21.8% to $6.58.</li>
<li>Ampio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ampe#NASDAQ">AMPE</a>) shares surged 21% to $2.3750 after gaining over 3% on Wednesday.</li>
<li>Reborn Coffee, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rebn#NASDAQ">REBN</a>) gained 19.5% to $0.6216. Reborn Coffee announced conversion of $1 million of outstanding debt into common equity.</li>
<li>Zuora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zuo#NASDAQ">ZUO</a>) gained 19.5% to $9.98 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>SpringWorks Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swtx#NASDAQ">SWTX</a>) climbed 18.3% to $31.75.</li>
<li>Jeffs&#39; Brands Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 17% to $3.65.</li>
<li>The InterGroup Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intg#NASDAQ">INTG</a>) rose 13.7% to $25.50.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) climbed 13.6% to $26.80 following third-quarter results.</li>
<li>VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) gained 11.7% to $8.44 after gaining around 8% on Wednesday.</li>
<li>Farfetch Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NYSE">FTCH</a>) rose 11.2% to $1.0842.</li>
<li>Salesforce, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>) shares gained 8.4% to $249.69 after the company reported third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Oatly Group AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otly#NASDAQ">OTLY</a>) gained 7.5% to $1.0750.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) climbed 7.1% to $187.76 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Nutanix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntnx#NASDAQ">NTNX</a>) rose 5% to $43.61 after the company reported better-than-expected first-quarter financial results and raised FY24 revenue guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvos#NASDAQ">VVOS</a>) shares fell 40.7% to $24.30. Vivos Therapeutics shares jumped around 832% on Wednesday after the company announced it received FDA 510(k) clearance for treating severe obstructive sleep apnea in adults using the Vivos&#39; removable CARE oral appliances.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) fell 35.6% to $1.8499 after gaining 26% on Wednesday. On Monday, Redhill Biopharma announced that the FDA had granted five years&#39; market exclusivity for its drug, Talicia, on top of three years&#39; exclusivity granted for the approval of Talicia.</li>
<li>POET Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poet#NASDAQ">POET</a>) fell 31.4% to $0.7603 after the company reported pricing of $1.4 million underwritten public offering of common shares and warrants.</li>
<li>Elevai Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elab#NASDAQ">ELAB</a>) fell 28% to $2.54.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) fell 26.8% to $2.2226.</li>
<li>PROOF Acquisition Corp I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/paci#NASDAQ">PACI</a>) declined 25% to $24.00.</li>
<li>Lizhi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lizi#NASDAQ">LIZI</a>) fell 21.5% to $2.9750 following third-quarter results.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) declined 14.6% to $22.45.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crev#NASDAQ">CREV</a>) fell 14.3% to $33.00.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) fell 14.2% to $32.54 after the company reported worse-than-expected third-quarter revenue results and issued FY24 revenue guidance below estimates.</li>
<li>Nvni Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvni#NASDAQ">NVNI</a>) shares fell 12.2% to $2.03 after gaining over 5% on Wednesday.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) fell 11.8% to $25.55 following FY23 results.</li>
<li>Weibo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wb#NASDAQ">WB</a>) declined 11.5% to $10.02 after the company announced a proposed offering of $300 million convertible senior notes and a proposed offering of ADSs in connection with the Delta Placement of Borrowed ADSs.</li>
<li>BRP Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dooo#NASDAQ">DOOO</a>) fell 10.6% to $62.48 following third-quarter results.</li>
<li>Movado Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mov#NYSE">MOV</a>) fell 9.4% to $26.25 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) fell 9.4% to $2.40 after dipping 14% on Wednesday.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) shares fell 6.7% to $19.77 following downbeat third-quarter earnings.</li>
<li>Cracker Barrel Old Country Store, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbrl#NASDAQ">CBRL</a>) declined 6.5% to $70.21 following weak results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/36016689/how-to-make-500-a-month-with-pfizer-stock"> How To Make $500 A Month With Pfizer Stock</a>

ADTX

AGRI

AMPE

ARWR

CMND

CREV

ELAB

FTCH

GYRE

INTG

JFBR

MINM

NTNX

NVNI

OTLY

PACI

RDHL

REBN

Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Comments

REX American Resources

Vendite allo scoperto

REX American Resources (NYSE:REX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO